ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,887 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBellinzonaHumabs BioMed SA
Humabs BioMed SA Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of Humabs BioMed SA is the discovery and development of anti-infective immunotherapies for the treatment of viral and bacterial diseases, including those caused by Zika, Ebola, Rabies, Dengue and other Flaviviruses. The company focuses on the development of therapeutics up to clinical proof of concept and has a broad pipeline of development candidates.

AI-generated
Offering

Products & services

LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Humabs BioMed SA

Industry:Research & DevelopmentPharmaceutical Industry
✓ Offered7
Development of Immunotherapies
Development of antibody- and T-cell engager–based therapeutics for infectious diseases, cancer and other serious conditions with high unmet medical need.
Antibody and T-cell Engager Development Platform
Platform for the identification, optimisation and further development of antibodies, antibody fragments and T-cell engagers using proprietary discovery methods and AI-supported protein engineering tools.
PRO-XTEN® Masking Platform
Protease-cleavable masking platform for targeted activation of therapeutics in the tumour microenvironment, focusing on T-cell engagers and other applications in oncology and infectious diseases.
Treatment of chronic hepatitis delta
Development of a chronically suppressive therapy with tobevibart and elebsiran; ongoing Phase 3 programme for the treatment of chronic hepatitis delta.
Oncology Therapies
Development of PRO-XTEN®-masked T-cell engagers against HER2, EGFR and PSMA, as well as other undisclosed targets for solid tumours.
HIV cure programs
Development of preclinical antibody candidates and broadly neutralising antibodies with Fc technology to pursue an HIV cure approach, supported by the Gates Foundation.
Out-licensing of programs
Openness to partnership discussions for out-licensing additional programmes in hepatitis B, influenza, COVID-19 and HPV.
Trust & reputation

ranQ Trust Score of Humabs BioMed SA: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

Without public customer reviews the score stays capped.

Humabs BioMed SA has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Humabs BioMed SA scores 89.3 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.100.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.70.07%
Humabs BioMed SA scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Humabs BioMed SA scores 55.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.10.04%
Qualifications+0.00

Humabs BioMed SA reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

September 25, 2017Media
Humabs BioMed acquired by Vir Biotechnology
startupticker.ch

Knowledge

No knowledge articles yet

Once Humabs BioMed SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Humabs BioMed SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Humabs BioMed SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Humabs BioMed SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Via dei Gaggini 3
6500 Bellinzona

At a glance

Legal form
Corporation
UID
CHE-308.820.942
Founded
2011 · 15 years
Last commercial register change
October 6, 2025
Employees
11 to 20
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    TS
    Tecnomedia Service Sagl
    Bellinzona
    DS
    DEVINTEC Sagl
    Lugano
    AP
    Alpex Pharma SA
    Mezzovico
    GG
    GT Gain Therapeutics SA
    Lugano
    IS
    Innocenti SA
    Lugano
    MR
    MA R&D Sagl
    Minusio
    GG
    GRG Gene Technology SA
    Contone
    SS
    SOLS SA
    Chiasso